Free triiodothyronine is associated with the occurrence and remission of nonalcoholic fatty liver disease in euthyroid women.


Journal

European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 31 07 2018
revised: 01 11 2018
accepted: 23 11 2018
pubmed: 14 1 2019
medline: 18 12 2019
entrez: 14 1 2019
Statut: ppublish

Résumé

The association between nonalcoholic fatty liver disease (NAFLD) and free triiodothyronine (FT3) in euthyroid subjects was in dispute. We aimed to investigate this issue in a population-based cohort study. A total of 3144 euthyroid subjects at baseline from the Shanghai Nicheng Atherosclerosis Study were selected for the cross-sectional analysis, and 2089 subjects being followed up after 2.2 years were selected for the longitudinal analysis. NAFLD was diagnosed by ultrasound. The cut-off point of elevated alanine aminotransferase (ALT) level was 40 U/L. The FIB-4 index was used to assess the risk of advanced liver fibrosis. Age-adjusted mean levels of FT3 and FT3/free thyroxine (FT4) ratio were higher in subjects with NAFLD than those without NAFLD and linearly increased with a higher risk of NAFLD progression (assessed by levels of ALT and FIB-4 index) in euthyroid women but not in men. After adjustment for confounding variables, FT3 levels significantly increased with the presence of NAFLD (β = 0.1, P < 0.001) and linearly increased with a higher risk of NAFLD progression in euthyroid women. After a 2.2-year follow-up, FT3 levels increased with the occurrence of NAFLD (mean change percentage: 1.4%) and decreased with the remission of NAFLD (mean change percentage: -2.7%) in euthyroid women. There are positive associations of FT3 levels with NAFLD and the risk of NAFLD progression in euthyroid women. The changes in FT3 levels with the alteration of NAFLD status may be an adaptive response to maintain energy and metabolic homeostasis.

Sections du résumé

BACKGROUND BACKGROUND
The association between nonalcoholic fatty liver disease (NAFLD) and free triiodothyronine (FT3) in euthyroid subjects was in dispute. We aimed to investigate this issue in a population-based cohort study.
MATERIALS AND METHODS METHODS
A total of 3144 euthyroid subjects at baseline from the Shanghai Nicheng Atherosclerosis Study were selected for the cross-sectional analysis, and 2089 subjects being followed up after 2.2 years were selected for the longitudinal analysis. NAFLD was diagnosed by ultrasound. The cut-off point of elevated alanine aminotransferase (ALT) level was 40 U/L. The FIB-4 index was used to assess the risk of advanced liver fibrosis.
RESULTS RESULTS
Age-adjusted mean levels of FT3 and FT3/free thyroxine (FT4) ratio were higher in subjects with NAFLD than those without NAFLD and linearly increased with a higher risk of NAFLD progression (assessed by levels of ALT and FIB-4 index) in euthyroid women but not in men. After adjustment for confounding variables, FT3 levels significantly increased with the presence of NAFLD (β = 0.1, P < 0.001) and linearly increased with a higher risk of NAFLD progression in euthyroid women. After a 2.2-year follow-up, FT3 levels increased with the occurrence of NAFLD (mean change percentage: 1.4%) and decreased with the remission of NAFLD (mean change percentage: -2.7%) in euthyroid women.
CONCLUSIONS CONCLUSIONS
There are positive associations of FT3 levels with NAFLD and the risk of NAFLD progression in euthyroid women. The changes in FT3 levels with the alteration of NAFLD status may be an adaptive response to maintain energy and metabolic homeostasis.

Identifiants

pubmed: 30636282
doi: 10.1111/eci.13070
doi:

Substances chimiques

Triiodothyronine 06LU7C9H1V
Thyrotropin 9002-71-5
Alanine Transaminase EC 2.6.1.2
Thyroxine Q51BO43MG4

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13070

Subventions

Organisme : National Natural Science Foundation of China
ID : 81202273
Organisme : Shanghai Pujiang Talent Program
ID : 12PJ1407000
Organisme : Shanghai Health and Family Planning Commission
ID : 2013ZYJB1001
Organisme : Biomedical Engineering Cross Research Foundation of Shanghai Jiao Tong University
ID : YG2015MS18

Informations de copyright

© 2019 Stichting European Society for Clinical Investigation Journal Foundation.

Auteurs

Peizhu Chen (P)

Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Shanghai Diabetes Institute, Shanghai, China.
Shanghai Clinical Center for Diabetes, Shanghai, China.
Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.

Xuhong Hou (X)

Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Shanghai Diabetes Institute, Shanghai, China.
Shanghai Clinical Center for Diabetes, Shanghai, China.
Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.

Li Wei (L)

Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Shanghai Diabetes Institute, Shanghai, China.
Shanghai Clinical Center for Diabetes, Shanghai, China.
Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.

Liang Feng (L)

Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

Lichang Zhong (L)

Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

Lei Jiao (L)

Department of Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

Hongmei Wang (H)

Department of Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

Yuqian Bao (Y)

Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Shanghai Diabetes Institute, Shanghai, China.
Shanghai Clinical Center for Diabetes, Shanghai, China.
Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.

Weiping Jia (W)

Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Shanghai Diabetes Institute, Shanghai, China.
Shanghai Clinical Center for Diabetes, Shanghai, China.
Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH